Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report)'s stock price gapped down prior to trading on Monday . The stock had previously closed at $17.15, but opened at $16.25. Telix Pharmaceuticals shares last traded at $16.22, with a volume of 18,490 shares traded.
Wall Street Analysts Forecast Growth
Several analysts have commented on TLX shares. Wedbush restated an "outperform" rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a report on Thursday, June 12th. William Blair restated an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday, March 12th.
Get Our Latest Research Report on Telix Pharmaceuticals
Telix Pharmaceuticals Stock Performance
The stock has a fifty day moving average of $17.07 and a two-hundred day moving average of $16.95. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.78 and a quick ratio of 2.66.
Hedge Funds Weigh In On Telix Pharmaceuticals
A hedge fund recently bought a new stake in Telix Pharmaceuticals stock. Private Advisor Group LLC acquired a new stake in Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,140 shares of the company's stock, valued at approximately $170,000.
About Telix Pharmaceuticals
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
